Botulinum toxin

Indian Journal of Dermatology

Volumn 55, Issue 1, 2010, Pages 8-14

  Nigam, P ^a,b   Nigam, Anjana ^a  

^a STD   (India)

^b PT J N M MEDICAL COLLEGE   (India)

Author keywords

Adverse effects; Botulinum toxin; Clinical applications; Clostridium botulinum

Indexed keywords

ACETYLCHOLINE; APRACLONIDINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN C 2; BOTULINUM TOXIN C1; BOTULINUM TOXIN E; BOTULINUM TOXIN F; BOTULINUM TOXIN G; EYE DROPS; NEUTRALIZING ANTIBODY; PHENYLEPHRINE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLOSTRIDIUM BOTULINUM; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; ELECTROMYOGRAPHY; ESTHETICS; FOCAL DYSTONIA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALAISE; MOTOR DYSFUNCTION; NAUSEA; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; NONHUMAN; PARALYSIS; PARESTHESIA; PTOSIS; REVIEW; SEROTYPE; SKIN MANIFESTATION; SPASTICITY; STRABISMUS; TREATMENT RESPONSE;

EID: 77949566453     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.60343     Document Type: Review

References (38)

1. Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ 2000;320:161-165
2. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Trans Am Ophthalmol Soc 1981;79:734-770
3. Ellenhorn MJ, Barceloux DG, editors. Medical Toxicology. Diagnosis and Treatment of Human Poisoning. New York: Elsevier; 1988. p. 1185-1187
4. Brin MF. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;20:146-168
5. Sellin LC. The pharmacological mechanism of botulism. Trends Pharmacol Sci 1985;6:80-82
6. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol 1949;109:10-24.
7. Stanley EF, Drachman DB. Botulinum toxin blocks quantal but not non-quantal releasee of ACh at the neuro-muscular junction. Brain Res 1983;261:172-175
8. Hoffman RO, Helveston EM. Botulinum in the treatment of adult motility disorders. Int Ophthalmol Clin 1986;26:241-250
9. Priori A, Berardelli A, Mercuri B, Manfredi M. Physiological effects produced by botulinum toxin treatment of upper limb dystonia: Changes in reciprocal inhibition between forearm muscles. Brain 1995;118:801-807
10. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies and therapeutic consequences. Exp Neurol 1997;147:96-102.
11. Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol 1999;38:641-655
12. Jankovic J, Brin MF. Botulinum toxin: Historical perspective and potential new indications. Muscle Nerve Suppl 1997;20:129-145
13. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardization of Botulinum toxin. J Neurol Neurosurg Psychiatry 1995;19:102-103
14. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
15. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovik J, Hallet M, eds. Therapy with Botulinum Toxin. Vol.109. New York, NY: Marcel Dekker; 1994. p. 10-24.
16. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438
17. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Therapy with Botulinum Toxin. J Neurol Neurosurg Psychiatry 2002;72:459 62.
18. Pramit S Malhotra, Daniel G Danahey. BOTOX® Injections to Improve Facial Aesthetics. eMedicine Available from: http:// www.emedicine.com/ent/ topic134.htm. [last accessed on 2010 Jan 1].
19. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry. 1998;64:577-580
20. Dolly JO. Therapeutic and research exploitation of botulinum neurotoxins. Eur J Neurol 1997;4: S5-10.
21. Relja MA, Korsic M. Treatment of Tension type headache by injection of botulinum toxin type A: Double blind placebo-controlled study. Neurology 1999;52:203.
22. Bhatia KP, Münchau A, Brown P. Botulinum toxin is a useful treatment in extensive drooling of saliva. J Neurol Neurosurg Psychiatry 1999;67:697-699
23. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998;38:227-229
24. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: Indications and outcome. Eur J Neurol 1997;4:15-S22.
25. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 1998;338:217-220
26. Cuillière C, Ducrotté P, Zerbib F, Metman EH, de Looze D, Guillemot F, et al. Achalasia: Outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 1997;41:87-92.
27. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998;38:227-229
28. Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997;42:973-975
29. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: A report of two cases (letter). J Neurol Neurosurg Psychiatry 1997;62:198.
30. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, et al. Generalised muscular weakness following botulinum toxin injections for dystonia: A report of 3 cases. J Neurol Neurosurg Psychiatry 1999;67:90-93
31. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N; Botox® Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A in patients with glabellar lines. Plast Reconstr Surg 2003;15:1089-1098
32. Glanzman RL, Gelb DJ, Drury I, Bromberg MB, Truong DD. Brachial plexopathy after botulinum toxin injections. Neurology 1990;40:1143.
33. Schnider P, Brichta A, Schmied M, Auff E. Gallbladder dysfunction induced by botulinum A toxin. Lancet 1993;342:811-812
34. Latimer PR, Hodgkins PR, Vakalis, Butler RE, Evans AR, Zaki GA. Necrotising fasciitis as a complication of botulinum toxin treatment. Eye 1998;12:51-53
35. Moore P, ed. Handbook of botulinum toxin. Oxford: Blackwell Science; 1995.
36. Dressler D, Saberi A. Antibody-Induced Failure of Botulinum Toxin Type B Therapy in de novo Patients. J Neurol Neurosurg Psychiatry 2007;78:108-109
37. Kauffman JA, Way JF Jr, Siegel LS, Sellin LC. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol 1985;79:211-217
38. Mezaki T, Kaji R, Brin MF, Hirota-Katayama M, Kubori T, Shimizu T, et al. Combined use of type A and F botulinum toxins for blepharospasm: A double-blind controlled trial. Mov Disord 1999;14:1017-1020